RBC on Apogee Therapeutics Inc (APGE): 'we remain bullish on APGE's outlook'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $70.00 price target on Apogee Therapeutics Inc (NASDAQ: APGE).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
